La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Lifecore Biomedical Gestione

Gestione criteri di controllo 1/4

Lifecore Biomedical's Il CEO è Paul Josephs, nominato in May2024, ha un mandato di meno di un anno. possiede direttamente 0.052% delle azioni della società, per un valore di $ 92.14K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 1.6 anni.

Informazioni chiave

Paul Josephs

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.05%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	1.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Jun 24

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Nov 30

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Nov 05

Landec Still In Play As An Activist Investment

Aug 20

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

May 25

AMMINISTRATORE DELEGATO

Paul Josephs

less than a year

Mandato

Mr. Paul Josephs is President, CEO & Director of Lifecore Biomedical, Inc. from May 20, 2024. Mr. Josephs is President & CEO of Woodstock Sterile Solutions, Inc. Mr. Josephs serves as Senior Vice President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
John Morberg	Executive VP	3.6yrs	US$927.10k	0.77% $ 1.4m
James Hall	Advisor	less than a year	US$1.76m	1.43% $ 2.7m
Albert Bolles	President of Curation Foods	2yrs	US$1.34m	1.41% $ 2.6m
Paul Josephs	President	less than a year	Nessun dato	0.052% $ 96.1k
Kipling Thacker	VP & Chief Scientist	1.3yrs	Nessun dato	Nessun dato
Aaron Perlitsh	Director of Internal Audit & Chief Compliance Officer	no data	Nessun dato	Nessun dato
Darren Hieber	Senior Vice President of Corporate Development & Partnerships	2.6yrs	Nessun dato	Nessun dato
Jackie Klecker	Executive VP & GM	2.6yrs	Nessun dato	Nessun dato
Matt Augustson	Senior Vice President of Information Technology	2.6yrs	Nessun dato	Nessun dato
Parker Javid	Vice President	no data	US$460.69k	Nessun dato

2.3yrs

Durata media

61yo

Età media

Gestione esperta: Il team dirigenziale di LFCR è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Josephs	President	less than a year	Nessun dato	0.052% $ 96.1k
Nelson Obus	Independent Director	5.8yrs	US$180.00k	0.29% $ 532.1k
Katrina Houde	Independent Chairman of the Board	5yrs	US$185.00k	0.19% $ 359.4k
Jeffrey Edwards	Independent Director	3.8yrs	US$183.33k	0.16% $ 298.0k
Joshua Schechter	Independent Director	3.8yrs	US$170.00k	0.19% $ 358.0k
Humberto Antunes	Independent Director	less than a year	Nessun dato	Nessun dato
Christopher Kiper	Independent Director	1.6yrs	Nessun dato	0.091% $ 168.4k
Paul Johnson	Independent Director	less than a year	Nessun dato	Nessun dato
Raymond Diradoorian	Independent Director	2.6yrs	US$50.00k	0.13% $ 239.9k
Jason Aryeh	Director	no data	Nessun dato	Nessun dato
Matthew Korenberg	Independent Director	less than a year	Nessun dato	Nessun dato
Nathaniel Calloway	Independent Director	1.6yrs	Nessun dato	0.091% $ 168.4k

1.6yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di LFCR non è considerato esperto (durata media del mandato 1.6 anni), il che suggerisce un nuovo consiglio.

Lifecore Biomedical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new directors

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

High number of new directors

Landec Corporation, Annual General Meeting, Nov 01, 2022

Recent updates

Lifecore Biomedical, Inc. announced delayed annual 10-K filing

Third quarter 2024 earnings released: EPS: US$0.48 (vs US$0.51 loss in 3Q 2023)

High number of new directors

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc

Price target decreased by 25% to US$6.00

Lifecore Biomedical, Inc. Announces Board Changes

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 86% to US$2.00

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec receives Nasdaq's notification on delayed annual report filing

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

High number of new directors

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

High number of new directors

Independent Director recently bought US$104k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Price target increased to US$15.00

Consensus revenue estimates fall by 66%

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)

Landec Still In Play As An Activist Investment

Independent Director Patrick Walsh has left the company

Consensus forecasts updated

Price target increased to US$14.40

Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020)

President of Lifecore exercised options to buy US$61k worth of stock.

Independent Director exercised options to buy US$106k worth of stock.

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

Price target decreased to US$13.25

President of Lifecore recently bought US$106k worth of stock